For CDH1, the mutation rates were consistent between CARIS and TCGA cohorts (9.7% vs. 9.4%), suggesting that CDH1 may play an important role in driving tumorigenesis in a subset of patients with GC. This evidence concerns the gene CDH1 and gastric cancer.